Background {#Sec1}
==========

To date, several high-throughput HLA typing methods using next-generation sequencing (NGS) have been developed \[[@CR1]--[@CR8]\]. In our previous study, we completely sequenced long-range PCR amplicons encompassing entire regions of each of the HLA genes (*HLA-A, -C, -B, -DRB1, -DQB1,* and *-DPB1*). PCR amplicons were subjected to transposase-based library construction and multiplex sequencing with the MiSeq sequencer. Paired-end reads of 2 × 300 bp enabled us to demonstrate phase-defined allele determination (also defined as HLA gene haplotypes) in 33 HLA homozygous samples, 11 HLA heterozygous samples, and 3 parent--child families. Our sequencing protocol and pipeline provided essentially complete phase-defined HLA gene sequences; however, it required complicated and labor-intensive workflows especially in the library preparation step. Most importantly, the method is not well adapted for processing multiple samples. In the present study, we developed a new library preparation method for NGS and applied it to 96 samples. Long-range PCR products of *HLA-B* spanning from promoters to 3′-UTRs were prepared and sequenced with the MiSeq sequencer via transposase-based library preparation. In the previous protocol, although the DNA amount of each library was strictly measured and the library size was validated using a BioAnalyzer before the sequencing step, it was difficult to equalize the DNA amount and molecular size of the libraries, resulting in variable numbers of reads in each sample. We observed dropouts of samples owing to insufficient reads. Here, we developed a **Be**ad-based **N**ormalization for **U**niform **S**equencing (BeNUS) procedure using three steps of bead purification. BeNUS can easily and precisely normalize the molar concentrations of up to 96 samples, not only simplifying the library preparation step but also permitting automation of HLA typing using NGS.

Results and discussion {#Sec2}
======================

PCR amplification of *HLA-B*and library preparation {#Sec3}
---------------------------------------------------

We applied long-range PCR to amplify *HLA-B*, which is known to be highly polymorphic. *HLA-B*-specific amplification products were obtained from 96 individuals. All 96 PCR amplicons were subjected to transposase-based library construction using the Nextera kit, which simultaneously fragments the DNA and adds adaptors needed for multiplex sequencing. We developed protocol steps using altered AMPure XP beads to normalize the molar concentrations of 96 samples. Each PCR amplicon was subjected separately to transposase-based library construction, whereby a sample-specific index was introduced. The Nextera kit can construct libraries of a broad size range. For phase-defined HLA sequencing, a library range of 500--1,000 bp is desirable. In the previous protocol \[[@CR1]\], the library size selection was achieved by cutting of agarose gel and checking using a BioAnalyzer, which is a very laborious step, especially for preparing multiple samples.

Our new method, BeNUS, which is described in detail in the Methods section, circumvents the gel cutting method and employs bead-based steps for library size selection as well as equalization of DNA molar concentrations in up to 96 samples. More specifically, three bead steps were performed: first, 20 μl of altered beads suspended in 20% PEG and 2.5 M NaCl solution was added to 50 μl of diluted PCR product, and the supernatant fraction containing the desired fragments (\<1,000 bp) was collected. Second, 5 μl of beads was added to the collected supernatant. Desired fragments of larger than 500 bp were bound to the beads, while smaller fragments remaining in the supernatant were discarded (Figure [1](#Fig1){ref-type="fig"}). After these two steps, the desired DNA fragments (500--1,000 bp) were selected (actual size: 492 to 1,625 bp, average size: 924 bp) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Finally, 20-fold diluted beads were added to the size-fractionated library. Small numbers of beads can bind saturated amounts of DNA because bound DNA is in proportion to the number of beads (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Eventually, the final DNA size, concentration, and thereby molar concentration were equalized (Additional file [3](#MOESM3){ref-type="media"}: Figure S3).Figure 1**Schematic workflow of BeNUS.** The BeNUS method was constructed using two categories of method, size selection **(A)** and normalization of DNA amount **(B)**. **(A)** Size selection using altered AMPure XP beads. For size selection, two different bead ratio conditions were applied according to DNA volume: 0.4× bead ratio for \<1,000 bp fragment size and 0.5× bead ratio for \>500 bp. After bead selection, DNA fragments ranging from 500 to 1,000 bp were bound to the beads. **(B)** Normalization of DNA amount using altered AMPure XP beads DNA fragments with target sizes ranging from 500 to 1,000 bp were selected for effective HLA gene haplotype phasing. The size selection and DNA amount also defined an actual molar concentration for bridge PCR to generate clusters in a flow cell, because DNA fragments of over 1,000 bp are not efficiently amplified. Only one bead reaction condition was applied to normalize the amount of DNA. This step enables a defined amount of DNA to be bound to the diluted beads. This step enables a defined amount of DNA to be bound to the diluted beads.

Complete sequencing of *HLA-B*for 96 samples {#Sec4}
--------------------------------------------

The Nextera-treated libraries from 96 *HLA-B* PCR amplicons were subjected to NGS sequencing. The distribution of reads among the 96 multiplexed indexes ranged from 0.2% to 1.55% as percentages of 24.6 million reads and 1.04 Â± 0.32% on average. Technical improvements in libraries preparation were clarified by comparison between our previous method, cutting of agarose gel followed by the BioAnalyzer, and BeNUS method. The distribution of respective read numbers by the previous method was 0.06% to 2.74% and the value by BeNUS method was 0.2 to 1.55% (Figure [2](#Fig2){ref-type="fig"}). Sequence reads of *HLA-B,* were aligned to the reference sequence at an average mapped rate of 99.63%, ranging from 99.11 to 99.87%. The average depth of the alignment before phasing was 6495.3× and the phased haplotype depth was 2097.8×. Of the 96 samples, heterozygous SNVs and indels were not observed in 8 samples (0605, 0607, 0645, 1057, 1169, 1184, 1199, and 1229) indicating completely homozygous haplotypes. Generally, MiSeq yields base errors at a rate of 0.8% with PCR free library preparation \[[@CR9]\]. In the result of these homozygous samples, the total error rate of sequencing reaction and PCR amplification was estimated to be as less than 1.2%. In our simulated alignment result, the maximum error rates in 300× and 200× average depth were 4.8% and 6%, respectively, and the minimum depth for complete phasing was approximately 800× average depth. We recognize phasing result is not only dependent on average depth but also on distance between two heterozygous SNVs and long insert library covering the two heterozygous SNVs. As a general method, we propose that sequence reads of at least 800× depth is valid for providing the phase-defined HLA sequences with for high accuracy (less than 5% error rate). All samples were completely phased by the phase-defined sequencing pipeline \[[@CR1]\], although six samples showed only 1 to 7 SNVs in one exon: samples 0785, 1018, 1117, and 1175 had 4, 7, 3, and 3 heterozygous SNVs in exon 2, respectively. Sample 1224 had 3 heterozygous SNVs in exon 3, whereas sample 0979 had one heterozygous SNV in exon 5 (Figure [3](#Fig3){ref-type="fig"}). All the above samples were also phased using partial phasing (Additional file [4](#MOESM4){ref-type="media"}: Figure S4). Allelic imbalance as a result of PCR is manifested by skewed allelic calls after HLA sequencing. Allelic imbalance of the PCR amplification of *HLA-B* was negligible, as judged by the ratio of sequencing depth between the two phased alignments; 1:1.68 at the maximum and 1:1.19 on average in heterozygous samples (Table [1](#Tab1){ref-type="table"}). Consequently, 192 haplotype sequences of 96 individuals, which include 28 different haplotype sequences, were constructed as phased allelic *HLA-B* sequences. In general, allelic imbalance after PCR amplification has been occasionally observed. Evidently, this problem is not specific to NGS analyses. If capture, NGS, or the analytical step are causes of allelic imbalance, we would observe the discrepancy between our NGS typing and SSO typing, which was not the case in the current study. The current protocol aimed at minimizing the disparity of each sample; this was achieved although not perfectly. The minimum depth could be important to obtain phase-defined sequences because lower depth could leave unphased region. However, complete phase-defined sequencing is dependent on the allelic type of the sample, thereby it is not easy to give an exact depth number to accomplish the sequencing in general. In the current study, the most important point of the current study was to obtain complete phase-defined sequences of 96 samples without any dropout, which was achieved using the current protocol.Figure 2**Percentage of read numbers among 96 multiplexing indexes.** The horizontal axis shows the 96 samples and the vertical axis shows read percentage among demultiplexed 96 FASTQ files. Red bars show distribution of read number in proportion to libraries prepared by BioAnalyzer and agarose gel size selection, and blue bars show result by BeNUS method. Sequence reads for each sample were counted for evaluation of the normalization step in library preparation.Figure 3**Alignment view of heterozygous samples showing several SNVs or a single SNV between two HLA allele sequences in one exon.** The horizontal axis shows the position in *HLA-B* and red boxes at the top are exon regions. The vertical axis of upper graph in each sample shows read depth at each position, and red and blue bars in lower region are aligned reads as read1 (red) and read2 (blue). In the read depth graph, the gray color denotes bases identical with the reference genome, and, green, blue, orange, and red colors denote bases different from reference genome as A, C, G and T, respectively. If a position has 2 colors, it means heterozygous SNV, meanwhile, 1 color at one position means homozygous SNV. Red arrow indicates positions of the heterozygous SNVs.

###### 

**Alignment of the** ***HLA-B*** **sequence and genotype in 96 samples**

  Sample   HLA-B SSO       HLA-B PSP\*    Depth                Note                                               
  -------- --------------- -------------- -------------------- ---------------------------- -------- ------------ --------------------------
  0554     HLA-B\*44:03    HLA-B\*40:06   HLA-B\*44:03:01:01   HLA-B\*40:06:01:01           1543.4   1114.5       
  0555     HLA-B\*40:01    HLA-B\*44:03   HLA-B\*40:01:02      HLA-B\*44:03:01              2228.5   2084.8       
  0556     HLA-B\*13:01    HLA-B\*46:01   HLA-B\*13:01:01      HLA-B\*46:01:01              860.5    765          
  0560     HLA-B\*13:01    HLA-B\*51:01   HLA-B\*13:01:01      HLA-B\*51:01:01              1416.5   1455.9       
  0605     HLA-B\*52:01    HLA-B\*52:01   HLA-B\*52:01:01:02   HLA-B\*52:01:01:02           6928.7   Homozygous   
  0607     HLA-B\*07:02    HLA-B\*07:02   HLA-B\*07:02:01      HLA-B\*07:02:01              7357.3   Homozygous   
  0616     HLA-B\*40:02    HLA-B\*52:01   HLA-B\*40:02:01      HLA-B\*52:01:01:02           513.2    500.6        
  0639     HLA-B\*40:06    HLA-B\*35:01   HLA-B\*40:06:01:01   HLA-B\*35:01:01:02           1758     1656.8       
  0642     HLA-B\*40:01    HLA-B\*35:01   HLA-B\*40:01:02      HLA-B\*35:01:01:02           2016.8   1545.3       
  0645     HLA-B\*54:01    HLA-B\*54:01   HLA-B\*54:01:01      HLA-B\*54:01:01              6537     Homozygous   
  0649     HLA-B\*55: 02   HLA-B\*40:02   HLA-B\*55:02:01      HLA-B\*40:02:01              1402.3   1635.5       
  0652     HLA-B\*15:01    HLA-B\*35:01   HLA-B\*15:01:01:01   HLA-B\*35:01:01:02           2395.4   2308.4       
  0658     HLA-B\*56:01    HLA-B\*44:03   HLA-B\*56:01:01      HLA-B\*44:03:01              1686.7   2074         
  0663     HLA-B\*13:01    HLA-B\*52:01   HLA-B\*13:01:01      HLA-B\*52:01:01:02           1538.1   1455.7       
  0666     HLA-B\*54:01    HLA-B\*38:02   HLA-B\*54:01:01      HLA-B\*38:02:01              2105     1790.8       
  0703     HLA-B\*55:02    HLA-B\*40:06   HLA-B\*55:02:01      HLA-B\*40:06:01:01           1173.1   1445.3       
  0735     HLA-B\*44:03    HLA-B\*38:02   HLA-B\*44:03:01      HLA-B\*38:02:01              2507.5   1998.5       
  0739     HLA-B\*40:02    HLA-B\*48:01   HLA-B\*40:02:01      HLA-B\*48:01:01              1947.1   2382.9       
  0741     HLA-B\*59:01    HLA-B\*07:02   HLA-B\*59:01:01:01   HLA-B\*07:02:01              1458.6   2336         
  0772     HLA-B\*07:02    HLA-B\*48:01   HLA-B\*07:02:01      HLA-B\*48:01:01              3512.9   3425         
  0779     HLA-B\*44:02    HLA-B\*39:01   HLA-B\*44:02:01:01   HLA-B\*39:01:01:03           1677.5   1060.6       
  0784     HLA-B\*40:06    HLA-B\*15:01   HLA-B\*40:06:01:01   HLA-B\*15:01:01:01           1875.1   1820.8       
  0785     HLA-B\*52:01    HLA-B\*51:01   HLA-B\*52:01:01:01   HLA-B\*51:01:01              6041.4   6018.4       Onlu 4 heterozygous SNVs
  0810     HLA-B\*40:02    HLA-B\*46:01   HLA-B\*40:02:01      HLA-B\*46:01:01              560.8    546.8        
  0815     HLA-B\*35:01    HLA-B\*07:02   HLA-B\*35:01:01      HLA-B\*07:02:01              1239.5   1740         
  0821     HLA-B\*40:01    HLA-B\*40:02   HLA-B\*40:01:02      HLA-B\*07:02:01              1239.5   1740         
  0821     HLA-B\*40:01    HLA-B\*40:02   HLA-B\*40:01:02      HLA-B\*40:02:01              2144.4   1925.5       
  0822     HLA-B\*54:01    HLA-B\*35:01   HLA-B\*54:01:01      HLA-B\*35:01:01              1550     1840.6       
  0823     HLA-B\*15:11    HLA-B\*07:02   HLA-B\*15:11:01      HLA-B\*07:02:01              703.5    914.6        
  0830     HLA-B\*51:01    HLA-B\*48:01   HLA-B\*51:01:01      HLA-B\*48:01:01              1833.8   2509         
  0969     HLA-B\*40:06    HLA-B\*51:01   HLA-B\*40:06:01:01   HLA-B\*51:01:01              1575.4   1650.4       
  0975     HLA-B\*44:03    HLA-B\*07:02   HLA-B\*44:03:01      HLA-B\*07:02:01              180.4    209.3        
  0976     HLA-B\*54:01    HLA-B\*35:01   HLA-B\*54:01:01      HLA-B\*35:01:01              3635.9   3759.2       
  0977     HLA-B\*44:02    HLA-B\*15:18   HLA-B\*44:02:01:01   HLA-B\*15:18:01              722.2    574.4        
  0979     HLA-B\*39:01    HLA-B\*39:01   HLA-B\*39:01:01:03   HLA-B\*39:01:03              2128     2125.7       Only 1 heterozygous SNV
  0991     HLA-B\*15:01    HLA-B\*39:01   HLA-B\*15:01:01      HLA-B\*39:01:01:03           1685.4   1551.3       
  0997     HLA-B\*15:01    HLA-B\*51:01   HLA-B\*15:01:01:01   HLA-B\*39:01:01:03           1685.4   1551.3       
  0997     HLA-B\*15:01    HLA-B\*51:01   HLA-B\*15:01:01      HLA-B\*51:01:01              2588     2692.1       
  0999     HLA-B\*48:01    HLA-B\*39:01   HLA-B\*48:01:01      HLA-B\*39:01:01:03           1470.4   1045.3       
  1009     HLA-B\*54:01    HLA-B\*39:01   HLA-B\*54:01:01      HLA-B\*39:01:01:03           326.8    294.7        
  1011     HLA-B\*52:01    HLA-B\*07:02   HLA-B\*52:01:01:02   HLA-B\*07:02:01              730.9    943.7        
  1012     HLA-B\*35:01    HLA-B\*48:01   HLA-B\*35:01:01:02   HLA-B\*48:01:01              1830.1   2482.1       
  1013     HLA-B\*54:01    HLA-B\*52:01   HLA-B\*54:01:01      HLA-B\*52:01:01:02           533.9    600.7        
  1014     HLA-B\*55:02    HLA-B\*51:01   HLA-B\*55:02:01      HLA-B\*51:01:01              970.1    1153.1       
  1016     HLA-B\*44:03    HLA-B\*35:01   HLA-B\*44:03:01      HLA-B\*35:01:01              739.7    655.5        
  1018     HLA-B\*46:01    HLA-B\*15:01   HLA-B\*46:01:01      HLA-B\*15:01:01:01           5360.8   5496.1       Only 7 heterozygous SNVs
  1030     HLA-B\*40:06    HLA-B\*07:02   HLA-B\*40:06:01:01   HLA-B\*07:02:01              1638.8   2668.6       
  1045     HLA-B\*15:11    HLA-B\*35:01   HLA-B\*15:11:01      HLA-B\*35:01:01:02           1597.5   1448.8       
  1056     HLA-B\*58:01    HLA-B\*67:01   HLA-B\*58:01:01      HLA-B\*67:01:01              2497.9   2214.5       
  1057     HLA-B\*40:02    HLA-B\*40:02   HLA-B\*40:02:01      HLA-B\*40:02:01              4113.6   Homozygous   
  1064     HLA-B\*40:06    HLA-B\*51:01   HLA-B\*40:06:01:01   HLA-B\*51:01:01              963.5    1048.8       
  1065     HLA-B\*54:01    HLA-B\*52:01   HLA-B\*54:01:01      HLA-B\*52:01:01:02           1213.9   1563.8       
  1071     HLA-B\*56:01    HLA-B\*40:06   HLA-B\*56:01:01      HLA-B\*40:06:01:01           4061.2   1223         
  1079     HLA-B\*40:02    HLA-B\*39:01   HLA-B\*40:02:01      HLA-B\*39:01:03              2319.8   1507.5       
  1082     HLA-B\*40:01    HLA-B\*51:01   HLA-B\*40:01:02      HLA-B\*51:01:01              639.3    542.7        
  1083     HLA-B\*59:01    HLA-B\*54:01   HLA-B\*59:01:01      HLA-B\*54:01:01              716.5    1208.2       
  1087     HLA-B\*44:03    HLA-B\*07:02   HLA-B\*44:03:01      HLA-B\*07;02:01              1975.5   2605.1       
  1095     HLA-B\*40:02    HLA-B\*54:01   HLA-B\*40:02:01      HLA-B\*51:01:01              946.4    962.2        
  1097     HLA-B\*40:01    HLA-B\*40:06   HLA-B\*40:01:02      HLA-B\*40:06:01:01           2642.2   1822.5       
  1110     HLA-B\*40:01    HLA-B\*51:01   HLA-B\*40:01:02      HLA-B\*51:01:01              1277.1   1156.9       
  1111     HLA-B\*54:01    HLA-B\*40:03   HLA-B\*54:01:01      HLA-B\*40:03                 831.3    943.7        
  1116     HLA-B\*52:01    HLA-B\*07:02   HLA-B\*52:01:01:02   HLA-B\*07:02:01              981.1    1535.6       
  1117     HLA-B\*52:01    HLA-B\*51:01   HLA-B\*52:01:01:02   HLA-B\*51:01:01              5900.6   6084.9       Only 3 heterozygous SNVs
  1119     HLA-B\*35:01    HLA-B\*07:02   HLA-B\*35:01:01:02   HLA-B\*07:02:01              921.3    1370.1       
  1129     HLA-B\*59:01    HLA-B\*40:02   HLA-B\*59:01:01:01   HLA-B\*40:02:01              1472.9   2178.5       
  1131     HLA-B\*44:03    HLA-B\*52:01   HLA-B\*44:03:01      HLA-B\*52:01:01:02           1519.9   1456.8       
  1142     HLA-B\*40:02    HLA-B\*39:04   HLA-B\*40:02:01      HLA-B\*39:04                 1253     886.5        
  1144     HLA-B\*44:03    HLA-B\*15:11   HLA-B\*44:03:01      HLA-B\*15:11:01              1061.7   993.2        
  1149     HLA-B\*44:03    HLA-B\*52:01   HLA-B\*44:03:01      HLA-B\*52:01:01:02           719.6    633.6        
  1154     HLA-B\*59:01    HLA-B\*40:02   HLA-B\*59;01:01:01   HLA-B\*40:02:01              146.2    171.8        
  1157     HLA-B\*35:01    HLA-B\*48:01   HLA-B\*35:01:01:02   HLA-B\*48:01:01              911      1077.3       
  1160     HLA-B\*59:01    HLA-B\*54:01   HLA-B\*59:01:01:02   HLA-B\*54:01:01              129.8    166.8        
  1161     HLA-B\*55:02    HLA-B\*51:01   HLA-B\*55:02:01      HLA-B\*51:01:01              402.5    366.6        
  1163     HLA-B\*56:01    HLA-B\*46:01   HLA-B\*56:01:01      HLA-B\*46:01:01              2048.1   2276.5       
  1165     HLA-B\*15:01    HLA-B\*07:02   HLA-B\*15:01:01:01   HLA-B\*07:02:01              688.1    907.3        
  1167     HLA-B\*40:06    HLA-B\*52:01   HLA-B\*40:06:01:01   HLA-B\*52:01:01:02           1486.7   4508.1       
  1169     HLA-B\*54:01    HLA-B\*54:01   HLA-B\*54:01:01      HLA-B\*54:01:01              7086.1   Homozygous   
  1171     HLA-B\*54:01    HLA-B\*44:03   HLA-B\*54:01:01      HLA-B\*44:03:01              1586.6   1833.9       
  1175     HLA-B\*15:11    HLA-B\*15:01   HLA-B\*15:11:01      HLA-B\*HLA-B\*15:01::01:01   5717.6   5693         Only 3 heterozygous SNVs
  1182     HLA-B\*55:02    HLA-B\*51:01   HLA-B\*55:02:01      HLA-B\*51:01:01              1156.6   1451.5       
  1183     HLA-B\*54:01    HLA-B\*35:01   HLA-B\*54:01:01      HLA-B\*35:01:01              1413.5   1537.7       
  1184     HLA-B\*52:01    HLA-B\*52:01   HLA-B\*52:01:01:02   HLA-B\*52:01:01:02           6701.3   Homozygous   
  1199     HLA-B\*51:01    HLA-B\*51:01   HLA-B\*51:01:01      HLA-B\*51:01:01              5229.1   Homozygous   
  1201     HLA-B\*44:03    HLA-B\*52:01   HLA-B\*44:03:01      HLA-B\*52:01:01:02           1990.6   1665.9       
  1203     HLA-B\*54:01    HLA-B\*52:01   HLA-B\*54:01:01      HLA-B\*52:01:01:02           1246.4   1313.2       
  1217     HLA-B\*40:01    HLA-B\*46:01   HLA-B\*40:01:02      HLA-B\*46:01:01              2225.1   1882.2       
  1224     HLA-B\*40:02    HLA-B\*40:03   HLA-B\*40:02:01      HLA-B\*40:03                 6306.5   6286.4       Only 3 heterozygous SNVs
  1225     HLA-B\*40:01    HLA-B\*44:03   HLA-B\*40:01:02      HLA-B\*44:03:01              1554     1399.6       
  1229     HLA-B\*52:01    HLA-B\*52:01   HLA-B\*52:01:01:02   HLA-B\*52:01:01:02           6748.5   Homozygous   
  1234     HLA-B\*44:03    HLA-B\*40:06   HLA-B\*44:03:01      HLA-B\*40:06:01:01           2490.3   1715.9       
  1236     HLA-B\*54:01    HLA-B\*40:06   HLA-B\*54:01:01      HLA-B\*40:06:01:01           1132.4   1244.4       
  1238     HLA-B\*40:02    HLA-B\*67:01   HLA-B\*40:02:01      HLA-B\*67:01:01              2040.9   1691         
  1239     HLA-B\*40:03    HLA-B\*51:01   HLA-B\*40:03         HLA-B\*51:01:01              1787     1789.8       
  1250     HLA-B\*44:03    HLA-B\*51:01   HLA-B\*44:03:01      HLA-B\*51:01:01              357.7    317.8        
  1259     HLA-B\*40:02    HLA-B\*07:02   HLA-B\*40:02:01      HLA-B\*07:02:01              1346.9   1934.4       
  1260     HLA-B\*40:06    HLA-B\*35:01   HLA-B\*40:06:01:01   HLA-B\*35:01:01:02           641.9    680.8        
  1265     HLA-B\*40:01    HLA-B\*40:06   HLA-B\*40:01:02      HLA-B\*40:06:01:01           2226.2   1691.7       

\*Phase defined sequencing pipeline.

After obtaining phase-defined HLA gene sequences for 192 haplotype sequences, we attempted to assign HLA allele numbers to these sequences by searching for known allele sequences in the IMGT/HLA database. We used phased *HLA-B* haplotype sequences that spanned all of the intronic and exonic regions as queries against genomic and CDS sequences in the database. The determined *HLA-B* allele calls in all samples were consistent with PCR-SSO and Omixon Target, although the PCR-SSO determined HLA allele numbers were limited to a 4-digit resolution.

Conclusions {#Sec5}
===========

We established a simple, high-throughput, high-resolution, and high-fidelity HLA sequencing and genotyping method, as a combination of the Nextera kit and our new BeNUS method. We successfully applied our method for *HLA-B* sequencing in 96 samples, without dropouts. By developing BeNUS, it becomes feasible to construct multi-libraries without agarose gel size selection and DNA density control of each library. This method would be greatly advantageous for clinical applications that require a user-friendly and cost-effective protocol, with high throughput and accuracy. Our protocols open a way to prepare NGS libraries for large-scale HLA gene sequencing and typing using an automated system.

Methods {#Sec6}
=======

Subjects {#Sec7}
--------

A total of 96 unrelated healthy Japanese control subjects were recruited at the Health Evaluation and Promotion Center of Tokai University Hospital. All subjects gave written informed consent for the study. Ethical approvals for this study protocol were obtained from the IRBs of National Institute of Genetics and Tokai University School of Medicine.

DNA samples {#Sec8}
-----------

DNA samples were extracted from peripheral blood using a DNA extraction kit Genomix (Biologica, Nagoya, Japan) using the manufacturer's instructions.

HLA genotyping with PCR-SSO method {#Sec9}
----------------------------------

We genotyped *HLA-B* using the Luminex assay system and HLA typing kits (WAKFlow HLA Typing kits, Wakunaga, Osaka, Japan or LABType SSO, One Lambda, Canoga Park, CA, USA).

Library preparation {#Sec10}
-------------------

*HLA-B* was amplified using locus-specific primers by long-range PCR \[[@CR1]\]. Each amplification reaction contained 20 ng of genomic DNA, 0.25 unit of PrimeSTAR® GXL DNA polymerase (TAKARA BIO Inc., Shiga, Japan), 1× PrimeSTAR® GXL buffer (Mg^2^+ concentration 1 mM), 0.2 mM of each dNTP, and 0.2 μM of each primer in a 10 μl reaction volume. Cycling parameters were as follows: initial denaturation of 94°C for 2 min followed by 30 cycles of 98°C for 10 s, 60°C for 15 s, and 68°C for 5 min. Each PCR product concentration was measured with a Qubit dsDNA BR Assay Kit (Life Technologies, Carlsbad, CA, USA). PCR products were subjected to library preparation with a Nextera DNA Sample Preparation Kit (Illumina, San Diego, CA, USA) and a KAPA Library Amplification kit (Kapa Biosystems, Inc., Wilmington, MA, USA). The KAPA kit was used for library amplification because of its advantage of coverage depth in high-GC-content regions during library amplification (Additional file [5](#MOESM5){ref-type="media"}: Figure S5). Each sample was dual indexed and normalized with modified AMPure XP beads (Beckman Coulter Inc., Brea, CA, USA) method, which include optimal size selection and normalization of DNA concentration (Figure [1](#Fig1){ref-type="fig"}).

BeNUS for 96-well plate-based library {#Sec11}
-------------------------------------

We prepared altered AMPure XP beads by resuspending the beads in half of the original volume of 20% polyethylene glycol 8000 (PEG) and 2.5 M NaCl solution. The resuspended beads were twice as concentrated as the standard AMPure XP beads (Additional file [6](#MOESM6){ref-type="media"}: Figure S6). The optimal volume ratio of altered beads to DNA solution was determined by relation between the PEG--NaCl concentration and the selected DNA fragment size (Additional file [6](#MOESM6){ref-type="media"}: Figure S6). For library size selection, 20 μl of resuspended altered beads was added to 50 μl of diluted library (5 μl of PCR product and 45 μl of water), mixed well by pipetting at least 10 times, and incubated for 5 min at room temperature. The tube was placed on the NGS MagnaStand (NIPPON Genetics, Tokyo, Japan) to separate the beads from the supernatant. After separation, the supernatant was carefully transferred to a new tube. Five μl of the altered beads were added to the supernatant, mixed, and incubated, and the beads were then separated from the supernatant on the same conditions. The supernatant containing unwanted DNA was carefully removed. One hundred μl of 80% ethanol was added to the tube for washing and the supernatant was carefully discarded after incubation and separation. The beads were air-dried for 10 min while the tube was on the magnetic stand with the lid open. The target library was eluted from the beads into 22 μl of water (Figure [1](#Fig1){ref-type="fig"}). Next, to normalize DNA concentration, altered beads, which were diluted 20 fold with 20% PEG and 2.5 M NaCl solution, were used to capture a certain amount of DNA (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Twenty μl of 20-fold diluted altered beads and 20 μl of isopropanol were added to the 20 μl of size-selected library, mixed well by pipetting at least 10 times, and incubated for 5 min at room temperature. The tube was placed on the magnetic stand to separate the beads from the supernatant. After the supernatant was discarded, 100 μl of 80% ethanol was added to the tube kept on the magnetic stand and incubated at room temperature for 30 s, and then the supernatant was carefully discarded. The beads were air-dried, and then 20 μl of water was added to elute the normalized libraries (Figure [1](#Fig1){ref-type="fig"}). The combination of fragment size selection and normalization of DNA amount results in an equalized DNA molar concentration among 96 libraries.

Sequencing {#Sec12}
----------

Equal volumes of libraries were pooled and subjected to multiplex sequencing on the MiSeq sequencer (Illumina). The MiSeq flow cell of 2 × 300 bp paired-end reads resulted in 11.6 million read pairs corresponding to 6 Gbp of valid sequence data without adapter sequence.

Determination of the *HLA-B*sequence {#Sec13}
------------------------------------

Sequence reads were distributed according to index information to assign samples. We used the phase-defined sequencing pipeline (<http://p-galaxy.ddbj.nig.ac.jp>) \[[@CR1], [@CR10]\], which include trimming low quality bases (Phred quality score \< Q20), selection of only long (\>200 bp) paired-end reads, alignment to reference sequence, SNVs and indel identification, and haplotype phasing. *HLA-B* sequence (UCSC hg19, chr6: 31,317,316 -- 31,331,864, complement) was used as reference sequence. After phasing, two BAM files were created as phased *HLA-B* alignments. The IGV genome viewer \[[@CR11]\] was used to visualize the alignment results. The consensus sequences in FASTQ or FASTA format were constructed for searching the IMGT/HLA (<http://www.ebi.ac.uk/imgt/hla/>) database to identify the HLA alleles. We used them as query for BLAT \[[@CR12]\] search to known HLA allele sequences in the database as complete matches of genomic sequence or CDS sequence. For validation, *HLA-B* genotype calls were compared with the result of PCR-SSO and Omixon Target HLA Typing (Omixon Inc., Budapest, Hungary) \[[@CR13], [@CR14]\].

Availability of supporting data {#Sec14}
-------------------------------

The data set associated with this project has been submitted to DDBJ Sequence Reads Archive (DRA accession number: DRA001289).
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